Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Receivables (2016 - 2025)

BioCorRx (BICX) has disclosed Receivables for 16 consecutive years, with $305485.0 as the latest value for Q4 2025.

  • Quarterly Receivables changed N/A to $305485.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $305485.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $305485.0 for FY2025, 41181.76% up from the prior year.
  • Receivables hit $305485.0 in Q4 2025 for BioCorRx, up from $35000.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $1.1 million in Q2 2022 to a low of $1500.0 in Q1 2021.
  • Historically, Receivables has averaged $243330.6 across 5 years, with a median of $109736.0 in 2024.
  • Biggest five-year swings in Receivables: surged 71598.0% in 2022 and later plummeted 98.68% in 2023.
  • Year by year, Receivables stood at $57859.0 in 2021, then skyrocketed by 173.13% to $158030.0 in 2022, then tumbled by 51.27% to $77006.0 in 2023, then skyrocketed by 307.98% to $314170.0 in 2024, then decreased by 2.76% to $305485.0 in 2025.
  • Business Quant data shows Receivables for BICX at $305485.0 in Q4 2025, $35000.0 in Q3 2025, and $204970.0 in Q2 2025.